FDA Approved Focus Leverage EntroGen's FDA-approved CRCdx product to position as a validated oncology diagnostic solution, targeting hospitals and clinics seeking compliant, scalable tests with proven regulatory clearance.

Lung Cancer Kits Explore upsell and cross-sell opportunities around EntroGen's somatic mutation kits for lung cancer to expand portfolio in targeted therapies, appealing to oncology centers integrating precision medicine workflows.

End-to-End Workflow Highlight the integrated hardware, reagents, and proprietary software across the workflow to appeal to labs looking to streamline operations, reduce handoffs, and improve turnaround times.

MedTech Partnerships Leverage the mid-market size and tech-enabled approach to partner with mid-to-large clinical laboratories and academic centers seeking scalable molecular diagnostic solutions with ongoing software updates.

Growth Footprint Position EntroGen as a growth opportunity within the molecular diagnostics space by aligning with market trends toward genomics, targeted therapies, and end-to-end automated workflows, supported by a revenue range indicative of expanding customer adoption.